Circulating enterolactone concentrations and prognosis of postmenopausal breast cancer: assessment of mediation by inflammatory markers

International Journal of Cancer

Volumn 143, Issue 11, 2018, Pages 2698-2708

  Jaskulski, Stefanie ^a   Jung, Audrey Y ^a   Behrens, Sabine ^a   Johnson, Theron ^a   Kaaks, Rudolf ^a   Thöne, Kathrin ^b   Flesch Janys, Dieter ^b   Sookthai, Disorn ^a   Chang Claude, Jenny ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

breast cancer mortality; enterolactone; inflammation; Lignans; mediation

Indexed keywords

C REACTIVE PROTEIN; ENTEROLACTONE; INTERLEUKIN 10; 2,3-BIS(3'-HYDROXYBENZYL)BUTYROLACTONE; BIOLOGICAL MARKER; GAMMA BUTYROLACTONE; LIGNAN;

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; BODY MASS; BREAST CANCER; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; POSTMENOPAUSE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; INFLAMMATION; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY;

4-BUTYROLACTONE; AGED; BIOMARKERS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFLAMMATION; LIGNANS; MIDDLE AGED; POSTMENOPAUSE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 85054088137     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.31647     Document Type: Article

References (50)

1. Adlercreutz H. Lignans and human health. Crit Rev Clin Lab Sci 2007;44:483–525
2. Mense SM, Hei TK, Ganju RK, et al. Phytoestrogens and breast cancer prevention: possible mechanisms of action. Environ Health Perspect 2008;116:426–33
3. Seibold P, Vrieling A, Johnson TS, et al. Enterolactone concentrations and prognosis after postmenopausal breast cancer: assessment of effect modification and meta-analysis. Int J Cancer 2014;135:923–33
4. Kyro C, Zamora-Ros R, Scalbert A, et al. Pre-diagnostic polyphenol intake and breast cancer survival: the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Breast Cancer Res Treat 2015;154:389–401
5. Kyro C, Hansen L, Frederiksen K, Norskov NP, Bach Knudsen KE, Eriksen AK, Holm M, Tjonneland A, Olsen A. Pre-diagnostic plasma enterolactone concentrations and breast cancer prognosis among postmenopausal women – The Danish Diet, Cancer and Health cohort. Clin Nutr, in press, 2017, pii: S0261-5614(17):31396-1. doi: 10.1016/j.clnu.2017.10.023. [Epub ahead of print
6. Wang LQ. Mammalian phytoestrogens: enterodiol and enterolactone. J Chromatogr B Analyt Technol Biomed Life Sci 2002;777:289–309
7. Bloedon LT, Balikai S, Chittams J, et al. Flaxseed and cardiovascular risk factors: results from a double blind, randomized, controlled clinical trial. J Am Coll Nutr 2008;27:65–74
8. Demark-Wahnefried W, Polascik TJ, George SL, et al. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev 2008;17:3577–87
9. Pan A, Demark-Wahnefried W, Ye X, et al. Effects of a flaxseed-derived lignan supplement on C-reactive protein, IL-6 and retinol-binding protein 4 in type 2 diabetic patients. Br J Nutr 2009;101:1145–9
10. Barre DE, Mizier-Barre KA, Stelmach E, et al. Flaxseed lignan complex administration in older human type 2 diabetics manages central obesity and prothrombosis – an invitation to further investigation into polypharmacy reduction. J Nutr Metab 2012;2012:585170
11. Han Y, Mao F, Wu Y, et al. Prognostic role of C-reactive protein in breast cancer: a systematic review and meta-analysis. Int J Biol Markers 2011;26:209–15
12. Asegaonkar SB, Asegaonkar BN, Takalkar UV, et al. C-reactive protein and breast cancer: new insights from old molecule. Int J Breast Cancer 2015;2015:145647
13. Ren GY, Chen CY, Chen GC, et al. Effect of flaxseed intervention on inflammatory marker C-reactive protein: a systematic review and meta-analysis of randomized controlled trials. Nutrients 2016;8:136
14. Eichholzer M, Richard A, Nicastro HL, et al. Urinary lignans and inflammatory markers in the US National Health and Nutrition Examination Survey (NHANES) 1999-2004 and 2005-2008. Cancer Causes Control 2014;25:395–403
15. Frankenfeld CL. Cardiometabolic risk factors are associated with high urinary enterolactone concentration, independent of urinary enterodiol concentration and dietary fiber intake in adults. J Nutr 2014;144:1445–53
16. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74
17. Allin KH, Nordestgaard BG, Flyger H, et al. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res 2011;13:R55
18. Villasenor A, Flatt SW, Marinac C, et al. Postdiagnosis C-reactive protein and breast cancer survivorship: findings from the WHEL study. Cancer Epidemiol Biomarkers Prev 2014;23:189–99
19. Flesch-Janys D, Slanger T, Mutschelknauss E, et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 2008;123:933–41
20. Labmaster. TR-FIA Kits, Finland: Labmaster, 1999. Available at http://www.labmaster.fi/index.php?cat=3&lang=en&project= [Accessed January 15, 2017]
21. Adlercreutz H, Wang GJ, Lapcik O, et al. Time-resolved fluoroimmunoassay for plasma enterolactone. Anal Biochem 1998;265:208–15
22. Baccarelli A, Pfeiffer R, Consonni D, et al. Handling of dioxin measurement data in the presence of non-detectable values: overview of available methods and their application in the Seveso chloracne study. Chemosphere 2005;60:898–906
23. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986;51:1173–82
24. VanderWeele TJ. Explanation in causal inference: methods for mediation and interactioned, New York: Oxford Univ. Press, 2015
25. Unit C-UCSC. Interpreting Coefficients in Regression with Log-Transformed Variables, Cornell-University Cornell Statistical Consulting Unit, 2012. Available at https://www.cscu.cornell.edu/news/statnews/stnews83.pdf [Accessed January 15, 2017]
26. VanderWeele TJ. Causal mediation analysis with survival data. Epidemiology 2011;22:582–5
27. Therneau TM, Grambsch P. Modeling survival data: extending the cox model (statistics for biology and health), New York: Springer, 2000
28. Richiardi L, Bellocco R, Zugna D. Mediation analysis in epidemiology: methods, interpretation and bias. Int J Epidemiol 2013;42:1511–9
29. Valeri L, VanderWeele TJ. SAS macro for causal mediation analysis with survival data. Epidemiology 2015;26:e23–4
30. Soerjomataram I, Louwman MW, Ribot JG, et al. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 2008;107:309–30
31. Kobayashi N, Hikichi M, Ushimado K, et al. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival. Clin Transl Oncol 2017;19:1232–40
32. Szklo M, Nieto F. J. Epidemiology: beyond the basics, 3rd ed. Burlington: Jones & Bartlett Learning, 2014
33. Valeri L, Vanderweele TJ. Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros. Psychol Methods 2013;18:137–50
34. Lin DY, Fleming TR, De Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med 1997;16:1515–27
35. Hertzmark E, Pazaris, M., Spiegelman, D. The SAS MEDIATE Macro, 2012. Available at https://cdn1.sph.harvard.edu/wpcontent/uploads/sites/271/2012/09/mediate_manual_2012_06_06.pdf [Accessed January 15, 2017]
36. Adlercreutz H, Fotsis T, Bannwart C, et al. Determination of urinary lignans and phytoestrogen metabolites, potential antiestrogens and anticarcinogens, in urine of women on various habitual diets. J Steroid Biochem 1986;25:791–7
37. Clavel T, Henderson G, Alpert CA, et al. Intestinal bacterial communities that produce active estrogen-like compounds enterodiol and enterolactone in humans. Appl Environ Microbiol 2005;71:6077–85
38. Grace PB, Mistry NS, Carter MH, et al. High throughput quantification of phytoestrogens in human urine and serum using liquid chromatography/tandem mass spectrometry (LC-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci 2007;853:138–46
39. Scott KP, Antoine JM, Midtvedt T, et al. Manipulating the gut microbiota to maintain health and treat disease. Microb Ecol Health Dis 2015;26:25877
40. Prasad K. Hypocholesterolemic and antiatherosclerotic effect of flax lignan complex isolated from flaxseed. Atherosclerosis 2005;179:269–75
41. Newairy AS, Abdou HM. Protective role of flax lignans against lead acetate induced oxidative damage and hyperlipidemia in rats. Food Chem Toxicol 2009;47:813–8
42. Kitts DD, Yuan YV, Wijewickreme AN, et al. Antioxidant activity of the flaxseed lignan secoisolariciresinol diglycoside and its mammalian lignan metabolites enterodiol and enterolactone. Mol Cell Biochem 1999;202:91–100
43. Lee JC, Bhora F, Sun J, et al. Dietary flaxseed enhances antioxidant defenses and is protective in a mouse model of lung ischemia-reperfusion injury. Am J Physiol Lung Cell Mol Physiol 2008;294:L255–65
44. Galland L. Diet and inflammation. Nutr Clin Pract 2010;25:634–40
45. Baranowski M, Enns J, Blewett H, et al. Dietary flaxseed oil reduces adipocyte size, adipose monocyte chemoattractant protein-1 levels and T-cell infiltration in obese, insulin-resistant rats. Cytokine 2012;59:382–91
46. Saarinen NM, Abrahamsson A, Dabrosin C. Estrogen-induced angiogenic factors derived from stromal and cancer cells are differently regulated by enterolactone and genistein in human breast cancer in vivo. Int J Cancer 2010;127:737–45
47. Chen J, Saggar JK, Corey P, et al. Flaxseed and pure secoisolariciresinol diglucoside, but not flaxseed hull, reduce human breast tumor growth (MCF-7) in athymic mice. J Nutr 2009;139:2061–6
48. Linseisen J, Rohrmann S. Biomarkers of dietary intake of flavonoids and phenolic acids for studying diet-cancer relationship in humans. Eur J Nutr 2008;47(Suppl 2):60–8
49. Bolvig AK, Kyro C, Norskov NP, et al. Use of antibiotics is associated with lower enterolactone plasma concentration. Mol Nutr Food Res 2016;60:2712–21
50. Zeleniuch-Jacquotte A, Adlercreutz H, Akhmedkhanov A, et al. Reliability of serum measurements of lignans and isoflavonoid phytoestrogens over a two-year period. Cancer Epidemiol Biomarkers Prev 1998;7:885–9